CONVENIENCE TRANSLATION FROM HEBREW -Agreement • October 29th, 2010 • Biocancell Therapeutics Inc. • Pharmaceutical preparations
WHEREAS, during the fourth quarter of 2010, the Company intends to publish a shelf offering report in Israel, according to which the Company shall offer to the public units comprising of (i) shares of common stock of the Company; (ii) series 3 warrants; and (iii) series 4 warrants (the “Units” and the “Offering”, respectively)
AGREEMENTAgreement • October 29th, 2010 • Biocancell Therapeutics Inc. • Pharmaceutical preparations
This agreement (the “Agreement”) effective as of October 28, 2010, is made between BioCancell Therapeutics Inc. of 8 Hartom St, Jerusalem, Israel, a company duly organized and existing under the laws of the state of Delaware (the “Company”), and Clal Finance Underwriting Ltd., of 37 Menachem Begin, Tel Aviv, a company duly organized and existing under the laws of the State of Israel (“Clal”). Each of the Company and Clal shall be known as a “Party” and together the “Parties”.
